Neoantigen Targeted Therapies Global Market Report 2024

The neoantigen targeted therapies market size has grown exponentially in recent years. It will grow from $2.43 billion in 2023 to $3.39 billion in 2024 at a compound annual growth rate (CAGR) of 39.3%. The growth observed during the historical period can be attributed to several factors, including advancements in genomic sequencing, the evolution of immunotherapy, increased understanding of tumor immunology, the successful implementation of checkpoint inhibitors in clinical settings, and progress in molecular profiling technologies.

The neoantigen targeted therapies market size is expected to see exponential growth in the next few years. It will grow to $11.69 billion in 2028 at a compound annual growth rate (CAGR) of 36.3%. The anticipated growth in the forecast period is expected to result from advancements in bioinformatics, the expansion of precision medicine, the development of neoantigen vaccines, the adoption of therapeutic combination strategies, and the validation of biomarkers. Noteworthy trends in the forecast period encompass the management of neoantigen resistance, the utilization of neoantigen-primed adoptive cell therapies, the exploration of neoantigen-based combinatorial therapies, the integration of real-world data, and the enhancement of predictive models.

The anticipated growth in the neoantigen targeted therapies market is primarily attributed to the increasing incidence of cancer cases. This refers to the rise in new cancer cases within a specific population during a given period. Neoantigen targeted therapies, often administered in combination, are instrumental in treating various types of cancer. In 2022, the American Cancer Society reported a substantial increase in new cancer cases in the United States, reaching 1.9 million. Additionally, 609,360 deaths were attributed to cancer in the same year, underscoring the profound impact of the disease. Consequently, the surge in cancer incidence is a key driver propelling the growth of the neoantigen targeted therapies market.

The growth of the market is expected to be fueled by the increasing prominence of precision oncology. Precision oncology involves tailoring cancer treatment based on detailed genetic and molecular information about a patient's tumor. Neoantigen-targeted therapies play a pivotal role in precision oncology by utilizing advanced genomic analysis to identify unique neoantigens expressed by an individual's cancer cells. This approach allows for a more personalized and effective treatment option, addressing the specific genetic makeup of each patient's tumor. The prevalence of precision oncology is evident in the increasing adoption of next-generation sequencing (NGS), with 60% of oncologists frequently using NGS in over 75% of cases, as reported by Novartis AG in its 2021 precision oncology annual trend report. This signifies a growing percentage of cancer patients benefiting from the precision oncology approach. Consequently, the rise of precision oncology is a key factor driving the growth of the neoantigen targeted therapies market.

Product innovation has become a prominent trend within the neoantigen targeted therapies market, with major players prioritizing the development of inventive products to establish leadership. A notable example is BioNTech, a Germany-based biotechnology company, which, in October 2021, expanded its clinical oncology portfolio by initiating a Phase 2 clinical trial for 'BNT122,' an mRNA-based individualized immunotherapy. This trial, focusing on colorectal cancer patients, represents a significant milestone, with the first patient dosed with BNT122. The innovative approach of stimulating a targeted T-cell response against neoantigens in each patient's tumor showcases BioNTech's commitment to advancing cutting-edge immunotherapies and broadening treatment options for cancer patients.

Key players in the neoantigen targeted therapies market are adopting a strategic partnership approach to personalize neoantigen vaccines and monoclonal antibody drugs, addressing challenges in existing immunotherapy for solid tumors. Strategic partnerships involve leveraging complementary strengths and resources for mutual benefits. An example is the partnership between Innovent Biologics, a China-based biopharmaceutical company, and NeoCura Bio-Medical Technology Co. Ltd., a China-based precision healthcare and medical technology company. Their collaboration, initiated in October 2021, aims to evaluate the combination therapy of sintilimab and the neoantigen vaccine NEO_PLIN2101 for cancer treatment in China, assessing safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy in cancer patients.

In August 2021, BioNTech SE, another Germany-based biotechnology company, acquired Kite Pharma's Neoantigen TCR cell therapy platform, further exemplifying the commitment to leveraging the immune system to combat cancer. This strategic move not only strengthens BioNTech's position in the innovative cell-based therapies field but also aligns with the company's broader goals in advancing cancer treatment. Kite Pharma, a US-based company specializing in cell therapy and immunotherapy, operates within the neoantigen targeted therapies market.

Major companies operating in the neoantigen targeted therapies market report are F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Kite Pharma Inc., Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Precision Biologics Inc., Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics PLC, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.

North America was the largest region in the neoantigen targeted therapies market in 2023. The regions covered in the neoantigen targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neoantigen targeted therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

These therapies fall into two main categories, monotherapy and combination therapy. Monotherapy involves utilizing a single medicine or therapeutic approach to address the disease. Immunotherapy options encompass DNA or RNA-based vaccines, protein-based vaccines, dendritic cell vaccines, and TIL-based therapies, with applications spanning colorectal cancer, renal cell carcinoma, non-small cell lung cancer, bone cancer, and gynecological cancer. Administration routes include intradermal, intravenous, and subcutaneous, while applications extend to medical research institutions, hospitals, clinics, and other healthcare settings.

The neoantigen targeted therapies market research report is one of a series of new reports that provides neoantigen targeted therapies market statistics, including the neoantigen targeted therapies industry global market size, regional shares, competitors with a neoantigen targeted therapies market share, detailed neoantigen targeted therapies market segments, market trends, and opportunities, and any further data you may need to thrive in the neoantigen targeted therapies industry. This neoantigen targeted therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neoantigen targeted therapies market consists of revenues earned by entities by providing services such as the identification and characterization of neoantigens in individual patients, the selection and administration of the appropriate therapy, and the monitoring of patients' responses. The market value includes the value of related goods sold by the service provider or included within the service offering. Neoantigen targeted therapies also include the sale of neoantigen-based cancer vaccines and genetically modified T cells. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.